Metsera is an obesity-focused biotech Pfizer acquired in November 2025 for approximately $10 billion, providing the anchor for Pfizer's next-generation obesity franchise. The lead asset MET-233i is a long-acting amylin analog peptide designed for monthly subcutaneous dosing, engineered with the same peptide-lipidation-plus-extended-half-life technology that has become the platform for the amylin class. MET-233i showed 8.4% placebo-adjusted weight loss at 36 days in Phase 1 monotherapy dosing, with an observed pharmacokinetic half-life of 19 days (dose to 50% of Cmax) that supports the monthly dosing target.
Metsera sits inside Pfizer's broader obesity discovery portfolio alongside the monthly GLP-1 receptor agonist berobenatide (PF-3944), which advanced with 10 planned Phase 3 studies presented at ADA 2026 in June. Pfizer's July 13, 2026 leadership change (Danna Breen named VP head of obesity discovery following Kendra Bence's departure) brings organizational continuity to both programs. The amylin class competitive set includes Zealand Pharma/Roche petrelintide (advancing to Phase 3 for chronic weight management), Alveus Therapeutics ALV-200 (highly selective AMYR3 agonist, $160M Series A January 2026), and Kalohexis MC3R/MC4R melanocortin program (confidential IPO filed July 2026).
Stories here cover Metsera trial readouts, Pfizer obesity strategy integration, and the amylin class positioning. See [[amylin]], [[pfizer]], and [[berobenatide]] for adjacent threads.
Pfizer (NYSE: PFE) in its Q2 2026 quarterly clearout discontinued clinical development of MET-224o, an oral fully-biased ultra-long-acting GLP-1 receptor agonist in Phase 1 for chronic weight management that came over in the $10 billion Metsera acquisition completed November 2025. MET-224o was developed by D&D Pharmatech (KOSDAQ: 259540) using its ORALINK oral peptide delivery platform. D&D Pharmatech stated the discontinuation was a strategic decision by Pfizer to focus on differentiated products as a late entrant in the oral obesity market rather than a technical issue with the platform. With MET-224o out, Pfizer's oral obesity pipeline collapses to a single asset: PF-08642534 (Pfizer's name for YP05002). The pruning continues Pfizer's pattern of aggressive Metsera-portfolio triage (a GIPR prospect was also dropped in the same clearout) and narrows an already-crowded oral GLP-1 field where Lilly's Foundayo (orforglipron) and Novo's Wegovy pill (oral semaglutide 25/50 mg) are already commercial.
Seoul Economic Daily published Monday August 17, 2026 a market synthesis on the obesity drug runner-up field. Key runners-up positioning for 2027-2028 approval filings behind Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO): Structure Therapeutics (NASDAQ: GPCR) with aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist) expected to initiate Phase 3 in H2 2026; Amgen (NASDAQ: AMGN) with MariTide (once-monthly injectable dual GIPR antagonist / GLP-1 agonist) now positioned as the sole obesity focus after the July 29 Q2 disclosure that Amgen halted AMG 513 Phase 1 development to concentrate resources on the MariTide MARITIME Phase 3 program; and Pfizer (NYSE: PFE) with danuglipron oral GLP-1 receptor agonist plus the Metsera acquisition pipeline. Amgen expects to apply for MariTide regulatory approval in late 2026 to early 2027. The Amgen MariTide Phase 3 program covers obesity (MARITIME-1) plus obesity and type 2 diabetes (MARITIME-2), with additional Phase 3 studies exploring cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea. The sorting of winners from losers based on Phase 3 results will begin in earnest starting next year as the field competes on efficacy, safety, delivery format, and price for market share behind Lilly's Zepbound-Mounjaro-Foundayo franchise and Novo's Wegovy-Ozempic franchise.
Pfizer (NYSE: PFE) reported Q2 2026 earnings Tuesday August 4, 2026 with revenue of $15 billion and adjusted diluted EPS of $0.77, beating analyst expectations. The company raised the midpoint of its full-year 2026 revenue guidance to $60.5-62.5 billion, up from a previous $59.5-62.5 billion range. The guidance update reflected approximately $1.5 billion in upside from non-COVID products, partially offset by a reduction in the company's forecast for COVID-19 treatments (Paxlovid and Comirnaty) now pegged at approximately $4 billion for the year. Adjusted R&D expenses increased 12% operationally to $2.7 billion, driven by increased spending on oncology and obesity product candidates. CEO Albert Bourla said in the earnings call that the obesity program is advancing with substantial momentum and that the oncology portfolio remains a source of strength. Shares rose approximately 1.86% to $25.50 following the announcement. Pfizer's obesity program includes danuglipron (oral GLP-1) and multiple next-generation candidates advanced through the Metsera acquisition; the Metsera monthly-injectable ultra-long-acting GLP-1 candidate produced up to 11% weight loss over 28 weeks in Phase 2b data reported earlier in 2026.
Pfizer (NYSE: PFE) named Danna Breen Vice President and head of obesity discovery on Monday July 13, 2026, following the departure of longtime scientific leader Kendra Bence. Bence had led internal medicine research across metabolic dysfunction-associated steatohepatitis (formerly known as NASH) and obesity discovery at Pfizer's Kendall Square research site for more than a decade, and described the role as 'the absolute privilege of my career' when announcing her exit. Breen advanced through multiple roles at Pfizer including Research Associate, Fellow, Senior Principal Scientist, Principal Scientist, and Senior Scientist, working on novel obesity drug targets and research collaborations. The role transition arrives as Pfizer's obesity portfolio expands substantially: the monthly GLP-1 receptor agonist berobenatide (PF-3944) is advancing through 10 planned Phase 3 studies presented at ADA 2026 in June, and the November 2025 $10 billion Metsera acquisition brought in the amylin peptide MET-233i (positive Phase 1 data supporting monthly dosing). Endpoints News concurrently reported AI startup Xaira making its own leadership adjustments as the sector's talent map continues to reshape.
Pfizer's ADA Phase 2b readout for berobenatide (15.9% weight loss at 32 weeks, no plateau, monthly dosing via a 0.5 mL low-volume injection) validates the $4.9 billion Metsera acquisition that closed earlier this year. The company now plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies. Monthly dosing positions berobenatide against once-weekly incumbents on the adherence axis, the same logic behind Amgen's MariTide and Ascletis's ASC30.
Pfizer presented Phase 2b VESPER-1 data for berobenatide (PF-07976094 / PF'3944), the ultra-long-acting injectable GLP-1 peptide engineered for monthly dosing through a 0.5 mL low-volume injection. At ADA 2026, the 2.4 mg weekly dose drove up to 15.9% mean weight loss at 32 weeks with no plateau across the VESPER program, plus improved glycemic control and favorable tolerability. Pfizer plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies of berobenatide in chronic weight management, knee osteoarthritis, and obstructive sleep apnea. The asset entered Pfizer's pipeline through the $4.9 billion Metsera acquisition.
Pfizer reported April 29 Q1 2026 revenue of $14.45 billion (vs. $13.92B consensus) and adjusted diluted EPS of $0.75 (vs. $0.72), with non-COVID operational revenue up 7%. The company reaffirmed 2026 guidance of $59.5–62.5B in revenue and $2.80–3.00 in adjusted EPS. On the obesity portfolio, Pfizer confirmed 20+ planned and ongoing studies across the diverse obesity pipeline acquired with Metsera, including 10 Phase 3 trials of PF'3944 (MET-097i) — the recently initiated Phase 3 VESPER-4 once-weekly study, the planned VESPER-5 in T2D, the planned VESPER-6 once-monthly maintenance study, and at least seven more. MET-233i, a monthly amylin analog, is in Phase 1 monotherapy and combination-with-PF'3944 development.